[Clinical significance of quantitative level of hepatitis B core antibody].

Hepatitis B core antibody (anti-HBc) targets viral core protein and is produced in patients with hepatitis B virus (HBV) infection, and seroconversion occurs in the early stage of infection and often lasts for a lifetime. Qualitative detection of anti-HBc has been used in clinical practice for many years, while the clinical significance of its quantitative level remains unclear. A novel anti-HBc immunoassay based on double-antigen sandwich ELISA has been developed in recent years and lays a foundation for illustrating the change in the quantitative level of anti-HBc (qAnti-HBc) in HBV infection and its clinical significance. Several recent studies have revealed that qAnti-HBc is associated with the degree of hepatitis activity and response to pharmacotherapy and may become an important basis for selecting antiviral drugs, optimizing therapeutic regimen, and predicting treatment outcome.乙型肝炎病毒核心抗体（抗-HBc）是乙型肝炎病毒（HBV）感染者产生的针对病毒核心蛋白的抗体，在感染早期即发生阳转，且常持续存在终生。抗-HBc的定性检测已在临床实践中应用多年，但其定量水平的临床意义尚不十分清楚。近年发展起来的基于双抗原夹心法的抗-HBc检测技术，为阐释抗-HBc定量水平（qAnti-HBc）在HBV感染中的变化规律及其临床意义奠定了基础。近年多项研究表明，qAnti-HBc与肝炎活动程度及药物治疗应答高度相关，有望成为抗病毒治疗药物选择、方案优化及疗效预测的重要依据。.